Overview

Enoxacin for Amyotrophic Lateral Sclerosis (ALS)

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety of the drug enoxacin at specific dose levels in adults with ALS.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
McGill University
Collaborators:
Apotex Inc.
Weizmann Institute of Science
Treatments:
Enoxacin